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Hepatitis B virus (HBV) is a global pandemic with over 350 million chronically infected individuals. 
Annually, 600,000 people die from HBV-related disease in the forms of cirrhosis and liver cancer. 
Despite the existence of an effective vaccine for over thirty years, HBV prevalence is still 
astoundingly high, especially in Southeast Asia, China and sub-Saharan Africa. Current therapy can 
only improve symptoms for a limited time, but does not eradicate the virus from the infected 
individual. Researchers in the laboratory of Dr. Keith Jerome (Vaccine and Infectious Disease 
Division) have proposed a novel curative approach to HBV infection. Via the use of targeted 
endonucleases HBV DNA can be specifically recognized and mutated, in effect rendering the viral 
genome incapable of replication. The results of applying this methodology in an in vitro model of 
HBV infection were recently published in PLoS ONE. 
In order to target the HBV genome in infected liver cells, several zinc finger nucleases (ZFNs) with 
specificity for HBV DNA sequences were designed. ZFNs consist of DNA recognition domains and 
cleavage domains, which dimerize upon recognition of their specific DNA target sequence, resulting 
in DNA cleavage. Following cleavage, DNA can undergo repair by a process called non-homologous 
end joining. However, this process can be error-prone, resulting in mutations such as small 
insertions or deletions, termed indels. If these indels appear in essential genes, the virus can be 
inactivated and replication halted. 
Proof-of-principle tests using HBV-specific ZFNs in mammalian cells showed the ability of the 
enzymes to knock down the expression of a reporter gene designed to contain the HBV target 
sequences. Indels were found precisely in the middle of the target sequences, indicating that 
recognition and cleavage had occurred (see Figure).  
Next, the potential for unwanted effects, such as cytotoxicity and off-target cleavage activity caused 
by the enzymes on host cells was examined. Cellular toxicity was detected for only one of the three 
enzymes. In an attempt to explain this toxicity, the researchers examined seven human DNA 
sequences with similarity to the HBV target sequences. Next generation sequencing was utilized to 
see if any of the sequences had been targeted and mutated when cells were treated with the ZFNs.  
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For the seven "off-target" sites, either minimal or no cleavage was detected. These data helped to 
establish whether the enzymes might be toxic or oncogenic to the host. 
A big issue to be addressed with gene therapy strategies is the question of efficient delivery to the 
target cells. Hepatocyte cells in the liver are the site of HBV infection and are highly accessible via 
intravenous injection into the blood. In order to transduce hepatocytes with DNA expressing the 
ZFNs, the researchers used a viral vector called adeno-associated virus (AAV). Before being able to 
transition into animal models, the efficiency of delivery required testing in liver cells in culture. Highly 
efficient and long-lasting transgene expression was achieved following a single administration of the 
AAV vectors.   
Lastly, ZFN-expressing AAV vectors were tested on an in vitro cell model for HBV infection. 
Following only a single dose of the AAV, HBV viral DNA was knocked down 200-fold and 26-fold in 
the supernatant and cells, respectively. The antiviral effect was also seen to last for at least 14 days. 
"We were happy to witness a high level of viral inhibition by our enzymes that was specific and 
sustained," said Dr. Daniel Stone, a contributor to the research. "The lack of toxicity and off-target 
cleavage was also significant." Looking ahead to the next steps in their research, he expects this 
antiviral strategy to continue to show high potential in pre-clinical studies. "Having already designed 
the delivery vectors for the enzymes, testing of their efficacy in a humanized mouse model for HBV 
infection is our next logical step." 
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Image taken from the manuscript. 
Tests on the ability to knock down the expression of a reporter gene by ZFNs. (a) Target sequences 
were cloned into plasmids expressing green fluorescent protein (GFP). (b) When cells expressing 
the GFP reporter were treated with ZFNs, specific GFP expression knockdown was observed. (c) 
DNA extracted from the treated cells revealed ZFN-induced insertions and deletions in the target 
sites. The centers of the target sites are underlined in the wild type (wt) sequences. 
 
